Trending Now
Unum Therapeutics Inc (NASDAQ:UMRX) Completes a Transaction Focused on the BOXR...
There are hundreds of inhibitors in the market today targeting mutant protein kinases. However, a majority of them do not have the required specificity....
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Electromedical Technologies Inc (OTCMKTS:EMED) Pioneers New Bioelectronic Medicine Path
Electromedical Technologies Inc (OTCMKTS:EMED) may be the most interesting player in the emerging space of bioelectronic medicine – a field that has recently spurred...
MAKE IT MODERN
LATEST REVIEWS
Top Energy Stock Opportunities as Oil Booms Higher (PXD, CEI, MTDR,...
The Oil market has been exploding higher since it found support in its crash following the emergence of the Omicron Covid-19 variant...
MAKE IT MODERN
PERFORMANCE TRAINING
ObsEva SA (NASDAQ: OBSV) Announces Two Poster Presentation at the 2021 ASRM Congress And...
ObsEva SA (NASDAQ: OBSV) has announced two imminent poster presentations on its oral GnRH antagonist, linzagolix, at the 2021 American Society for Reproductive Medicine...
ChromaDex Corp (NASDAQ:CDXC) Publishes Nutritional Protocol Study Results Showing Improved Recovery Time In COVID-19...
ChromaDex Corp (NASDAQ:CDXC) has announced the publication of results of the “Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19" study on the medRxiv.org.
COVID-19...
Aditxt Inc. (NASDAQ: ADTX) Signs Letter of Intent To Acquire the Target Company
Aditxt Inc. (NASDAQ: ADTX) has signed a letter of intent to purchase a biopharmaceutical firm, the "Target Company," which is marketing coronavirus antiviral oral...
Genmab (NASDAQ: GMAB) Reports 1H 2021 Revenue of DKK 2.55 Billion Driven by DARZALEX...
Genmab (NASDAQ: GMAB) has announced financial results for 1H 2021 and provided corporate updates.
1H 2021 DARZALEX revenue up 52%
In the first half of 2021,...
Coronavirus fears keep pushing SPY down
Futures are down this morning. The SPY is currently sitting at 324.98 in the premarket and has been moving up in the...
MAKE IT MODERN
